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1. Instrumentation
a. Analysis
FT-IR spectra were recorded with an Attenuated Total Reflection spectrophotometer (Agilent 
Technologies Cary 630 FTIR) equipped with a diamond single reflection ATR unit. Spectra were acquired 
with a resolution of 4 cm-1, in the range 4000-650 cm-1 by recording 32 interferograms.
1H and 13C {1H} NMR spectra were recorded at room temperature on a 400 MHz (Bruker DPX400 
Ultrashield) using deuterated solvents (CDCl3 or DMSO-d6). 2D 1H-13C HSQC NMR was used to aid peak 
assignments in 13C spectra. All chemical shifts are reported in parts per million (ppm). HSQC Mass spectra 
(TOF-ESI) were recorded on a Waters 2795 separation module/micromass LCT platform.
b. Size Exclusion chromatography (SEC)
The polymer molecular weights were determined by size exclusion chromatography (SEC) performed on a 
Polymer Laboratories GPC 50 system (Polymer Laboratories) equipped with RI detector. Separations were 
performed on a pair of Agilent PLgel 5 μm Mixed D columns (7.5 x 300 mm,5 μm bead size, Polymer Labs 
UK), eluting with DMF + 0.1 % w/w LiBr at flow rate of 1 mL min-1 and 100 µL injected onto the column. 
Samples were prepared at 5 mg mL-1 concentration. The molecular weights and polydispersity indices of the 
polymers were calculated according to a standard calibration method using PMMA narrow standards (505-
1,810,000 g mol-1). Data was elaborated with Polymer Labs Cirrus 3.0 Software.
2. Synthesis
Synthesis of methyl 2-((((2-hydroxyethyl)thio)carbonothioyl)thio)propanoate (MHP, 1) RAFT agent
The synthesis of the intermediate sodium 2-hydroxyethyl carbonotrithioate was performed according 
to a procedure we reported elsewhere.1 The RAFT chain transfer agent, methyl 2-((((2-
hydroxyethyl)thio)carbonothioyl)thio)propanoate (MHP) (scheme S1) was obtained by reacting the  
intermediate with methyl-2-bromo-propionate. 
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Scheme S1: Synthesis of methyl 2-((((2-hydroxyethyl)thio)carbonothioyl)thio)propanoate (MHP) chain 
transfer agent. Reagents and conditions: (a) i. NaH; ii. CS2, Et2O, 0°C; (b) methyl-2-bromo-propionate, 
acetone, 2 hours at RT.
Methyl 2-((((2-hydroxyethyl)thio)carbonothioyl)thio)propanoate (MHP)  (1). Sodium 2-hydroxyethyl 
carbonotrithioate intermediate (i) (4.00 g, 22.6 mmol) was suspended in acetone (50 mL) and methyl-2-bromo-
propionate (4.16 g, 24.9 mmol) was added dropwise under stirring. After 2 hours the solvent was removed 
under reduced pressure, the product was suspended in 50 mL of Et2O and washed with water (3x50 mL).  The 
organic layer was dried over MgSO4, filtered and the solvent evaporated under reduced pressure to give an 
orange viscous oil which was purified by flash chromatography (silicagel 60, 35-70 m) using petroleum 
ether/EtOAc 8:2 (vol/vol) as the eluent (4.14 g, 17.3 mmol, 76.5 %).
ESI-TOF mass spectrometry: expected m/z for [M+H]+ 240.99, found 240.76 Da FT-IR: ν 3426, 2950, 2874, 1733, 
1433, 1375, 1310, 1254, 1228, 1158, 1047, 1003, 855, 803 cm-1. 1H NMR (400 MHz, CDCl3, , ppm): 1.6 (d, J = 7.4 
Hz, 3H CH3CH), 1.82 (bs, 1H, OH), 3.61 (t, J = 5.9 Hz, 2H, CH2S), 3.75 (s, 3H, OCH3), 3.90 (t, 2H, J = 6.0 Hz, CH2OH), 
4.83 (q, J = 7.4 Hz, 1H, CHCH3). 13C {1H} NMR (100 MHz, CDCl3, δ, ppm): 16.9 (1C, CH3CH), 39.5 (1C, CH2S), 48.2 
(1C, CH), 53.1 (1C, OCH3), 60.43 (1C, CH2OH), 171.67 (1C, C=O), 221.92 (1C, C=S).
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Figure S1. 1H NMR spectrum of purified methyl 2-((((2-hydroxyethyl)thio)carbonothioyl)thio)propanoate 
(MHP) in CDCl3.
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Figure S2. 13C NMR spectrum of purified methyl 2-((((2-hydroxyethyl)thio)carbonothioyl)thio)propanoate 
(MHP) in CDCl3.
3. Methods
b. Loaded nanocarriers: drug content quantification. 
Terbinafine as a free base was obtained from commercial terbinafine HCl. 
Briefly, terbinafine.HCl (205 mg) was solubilised in DI water (100 mL). The pH was adjusted to 10 by 
dropwise addition of 0.1 N NaOH. The insoluble free base precipitated out of the solution and was 
extracted with CH2Cl2 (6x100 mL). The organic layers were combined and dried over MgSO4, filtered and the 
solvent was evaporated under reduced pressure to give terbinafine free base as a viscous oil. Presence of 
terbinafine as free base was confirmed by 1H NMR (Fig. S4 and S5) with the disappearance of the 
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hydrochloride proton at 10.5 ppm and a shift and change of the multiplicity of the vicinal methylene 
groups.
Terbinafine Hydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.50 (s, 1H), 8.32 (d, J = 8.3 Hz, 1H), 8.05 (dd, J = 
12.3, 8.2 Hz, 1H), 7.87 (d, J = 6.9 Hz, 1H), 7.62 (m, 1H), 6.20 (m, 1H), 6.04 (d, J = 15.8 Hz, 1H), 4.78 (ddd, J = 
20.5, 13.5, 5.5 Hz, 1H), 3.91 (m, 1H), 2.61 (d, J = 4.9 Hz, 1H), 1.23 (s, 1H).
Terbinafine free base, 1H NMR (400 MHz, DMSO-d6) δ 8.22 (m, 1H), 7.91 (dd, J = 6.5, 2.9 Hz, 1H), 7.81 (m, 
1H), 7.52 (m, 1H), 7.44 (d, J = 5.4 Hz, 1H), 6.05 (dt, J = 15.8, 6.5 Hz, 1H), 5.71 (d, J = 15.9 Hz, 1H), 3.11 (d, J = 
5.9 Hz, 1H).
Figure S3. Terbinafine hydrochloride 1H NMR spectrum in CDCl3.
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Figure S4. Terbinafine free base 1H NMR spectrum in CDCl3.
Drug loading was then quantified by RP-HPLC, using a Shimadzu HPLC (LC-20AD pump) equipped with a C18 
column (Jupiter, 5 μm, 250 x 46 mm, Phenomenex), SPD-M20A UV detector and SIL-20A autosampler and 
using milliQ water/0.1% TFA (eluent A) and acetonitrile/0.1% TFA (eluent B), as the mobile phase. For 
terbinafine, a linear gradient from 20% to 90% of eluent B concentration in 19 minutes was chosen, with 
detection at = 223 nm. Typically, 100 µL of polymersomes suspension, purified as described in the “drug 
loading procedure”, were diluted with 400 µL of MeOH, centrifuged at 5000 rpm for 5 minutes and finally 
50 µL of the resulting solution were analysed by HPLC. The amount of loaded terbinafine was calculated 
using a calibration curve previously obtained by analysis of terbinafine solutions at different concentrations 
(y =236481x+2E+06, R² = 0.9854, detection limit 1 µg mL-1). For cyanocobalamine, the eluent B 
concentration varied from 15% to 70% in 12 minutes. Before injection, 100 µL of loaded vesicles were 
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diluted with 400 µL of milliQ water, and 50 µL were subsequently analysed. Absorbance at = 360 nm was 
monitored, and drug loading was calculated using a standard curve prepared from cyanocobalamine 
standards (y =45621x+17543, R² = 0.9939, detection limit 1 µg mL-1).
Samples were prepared in triplicate and two independent experiments were performed.
4. Additional figures
Figure S5. 1H NMR spectrum of 2-(acryloyloxy)ethyl 3-chloro-4-hydroxybenzoate (ACH, 2) in CDCl3.
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Figure S6a. 13C NMR spectrum of 2-(acryloyloxy)ethyl 3-chloro-4-hydroxybenzoate (ACH, 2) in CDCl3.
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S6b. 1H-13C HSQC NMR spectrum of 2-(acryloyloxy)ethyl 3-chloro-4-hydroxybenzoate (ACH, 2) in MeOD.
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Figure S7. 1H NMR spectrum of 2-(3-chloro-4-hydroxybenzamido)ethyl acrylate (CHB, 3) in MeOD.
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Figure S8a. 13C NMR spectrum of 2-(3-chloro-4-hydroxybenzamido)ethyl acrylate (CHB, 3) in MeOD.
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S8b. 1H-13C HSQC NMR spectrum of 2-(3-chloro-4-hydroxybenzamido)ethyl acrylate (CHB, 3) in MeOD.
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Figure S9 1H NMR spectrum of non-purified PEGA12a (4) Tend in DMSO-d6.
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Figure S10 1H NMR spectrum of non-purified PEGA12b (5) Tend in DMSO-d6.
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Figure S11 1H NMR spectrum in DMSO-d6 of mPEGA12a-b-ACH36 (6) after purification by precipitation in 
Et2O.
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Figure S12 1H NMR spectrum in DMSO-d6 of mPEGA12b-b-CHB36 (7)  after purification by precipitation in 
Et2O.
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Figure S13 DLS analysis of mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36 polymersomes produced by 
nanoprecipitation method from DMSO/water. Data shown are representative of a single experiment. Sizes 
are reported as the mean of z-average of two different formulations.
Figure S14 TEM images of mPEGA12a-b-ACH36 polymersomes; 1.0 or 0.5 mg mL-1 solutions stained with 3% 
uranyl acetate.
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Figure S15 TEM images of mPEGA12b-b-CHB36 polymersomes, 1.0 or 0.5 mg mL-1 solution stained with 3% 
uranyl acetate.
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Figure S16 DLS analysis of mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36 vesicles produced by nanoprecipitation 
method from DMSO/PBS. Size is reported as z-average.
Figure S17 DLS analysis of different batches (A and B) of mPEGA12b-b-CHB36 polymersomes obtained from 
EtOH/water using the microfluidic device. Size is reported as z-average.
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